Surgery Partners (SGRY) Q1 2026 earnings review
Revenue Holds Steady, But Margin Compression Contradicts Cost Narrative
Surgery Partners delivered stable 4.5% revenue growth in Q1, reaching $810.9 million. However, the top-line stability masks a reversing trend in profitability. Adjusted EBITDA declined year-over-year to $102.3 million, and margins compressed by 80 basis points to 12.6%. Despite management touting 'cost management discipline' in the press release, operating expenses outpaced revenue gains. Compounding the issue, same-facility case growth decelerated sharply to just 0.6%. The company is now relying almost entirely on pricing power (revenue per case up 3.8%) and a shift toward high-acuity total joint procedures to maintain growth. With leverage sitting at a heavy 4.3x, the reaffirmed FY26 guidance leaves zero room for execution errors in the back half of the year.
🐂 Bull Case
Total joint cases grew 17% year-over-year, driving 65,000 musculoskeletal procedures in Q1. Capturing these high-margin, complex surgeries remains the strongest piece of the company's growth algorithm.
The company added 140 new physicians in Q1. As these recruits ramp up their case volumes over the next 12-18 months, they should provide a much-needed boost to organic growth.
🐻 Bear Case
Same-facility case growth plummeted to 0.6%. Without meaningful organic patient volume growth, the company is overly reliant on rate hikes, which face natural ceilings with commercial payers.
Despite rising revenue, Adjusted EBITDA fell year-over-year. Rising labor, general and administrative costs, and integration expenses are severely pressuring the bottom line.
⚖️ Verdict: ⚪
Neutral leaning Bearish. The pivot to higher-acuity procedures is a massive long-term tailwind, but near-term execution is flawed. Margins are compressing, organic volume is flat, and a 4.3x debt ratio acts as a heavy anchor on cash flow.
Key Themes
Margin Compression Contradicts Cost Discipline Claims
Reversing. Management explicitly praised their 'cost management discipline' in the earnings release, but the data tells the opposite story. Adjusted EBITDA fell to $102.3 million from $103.9 million a year ago. Margins compressed from 13.4% to 12.6%. General and administrative expenses jumped 9.2% to $39.3 million, far outpacing the 4.5% revenue growth. Cost structures are expanding faster than the top line.
Same-Facility Volumes are Stalling
Decelerating. Same-facility case growth collapsed to just 0.6% in Q1. To put this in perspective, case growth was 6.5% in 25Q1, 3.4% in 25Q2 and 25Q3, and 1.3% in 25Q4. The 4.4% same-facility revenue growth was entirely salvaged by a 3.8% increase in revenue per case. Pricing power cannot carry the algorithm indefinitely if patient volumes remain flat.
Higher-Acuity Migration and Robotics Adoption
Stable. The brightest spot in the report is the aggressive capture of high-acuity cases. Total joint procedures surged 17% year-over-year. The company completed roughly 65,000 musculoskeletal (MSK) procedures in the quarter. This validates their heavy prior investments in a fleet of 74+ surgical robots and targeted orthopedic physician recruiting.
Physician Recruitment Pipeline
Stable. Surgery Partners successfully recruited ~140 new physicians in Q1. Because new surgeons typically double their case volumes by their second year on the platform, this cohort is critical for reviving the currently stagnant same-facility case growth.
Portfolio Optimization Shift
Management noted ongoing portfolio optimization efforts to 'better align with our core short-stay surgical operating model.' This likely signals an acceleration of the strategy to divest or partner on larger, capital-intensive surgical hospitals to free up cash, lower leverage, and double down on pure-play Ambulatory Surgery Centers (ASCs).
Macro: Persistent Leverage and Interest Burden
Stable but restrictive. Net debt to EBITDA remains high at 4.3x. In Q1 alone, interest expense consumed $69.1 million, completely wiping out the $65.8 million in operating income. In an environment with lingering inflation and wage pressures, carrying nearly $3.7 billion in total debt severely limits management's flexibility to deploy capital for M&A without relying heavily on equity or divestitures.
Other KPIs
Accelerating from $6.0 million in the prior year period. However, this metric remains anemic relative to the company's scale. Operating Cash Flow moved positively while Net Income remained deeply negative (-$35.9 million). This divergence is primarily due to adding back $38.5 million in non-cash depreciation and amortization, and the heavy burden of $69.1 million in financing interest, which drags down earnings but is a required cash outflow.
Decelerating. Down significantly from $24.7 million in Q1 2025. While this is an improvement, spending $15.6 million in a single quarter on M&A integration and severance is still a material drag on cash generation for a company trying to deleverage.
Guidance
Decelerating. The midpoint of $3.40 billion implies approximately 2.7% full-year growth compared to FY25 actuals ($3.308 billion). This represents a deceleration from the 4.5% growth achieved in Q1, suggesting management is modeling for further softness or anticipating revenue loss from planned facility divestitures.
Stable. This implies roughly 0.7% growth over FY25's $526.2 million. However, to hit this target after a soft $102.3 million in Q1, the company will need to average ~$142 million per quarter for the rest of the year. This requires a steep margin acceleration in the second half.
Accelerating sequentially. Management indicated Q2 will represent 23.0% to 23.5% of the full-year EBITDA guide. This implies a significant quarter-over-quarter step up from Q1, heavily dependent on the maturation of new physician cohorts and favorable seasonal procedure volume.
Key Questions
Volume Plateau
With same-facility case growth decelerating sharply to 0.6%, have we hit a natural ceiling in your legacy markets, or is this a temporary disruption caused by physician retirements?
Margin Bridge to Guidance
Adjusted EBITDA margins compressed by 80 basis points year-over-year in Q1. Given persistent wage and supply inflation, what specific operational levers give you confidence you can achieve the aggressive margin acceleration required to hit the $530M+ full-year target?
Capital Deployment Constraint
With operating cash flow at just $11.7M for the quarter and leverage at 4.3x, how does the company plan to self-fund its historical target of $200M+ in annual M&A without tapping expensive capital markets?
Portfolio Optimization Timeline
Can you provide specific timelines or targets for the 'portfolio optimization' strategy? How much revenue base are you actively looking to divest to improve the balance sheet?